, Jim Cramer said Thursday on CNBC's Stop Trading! segment.
Cramer said he'd like to know more about the big biotech's drug pipeline, and the fact that management has been mum on the subject makes him "nervous." Even so he believes the risk is 3 points down and the potential reward is 7 points up.
Cramer said Amgen rival
also presents an attractive risk-reward balance now.
Cramer said he'd steer clear of
because of big writedowns possibly just around the corner. Cramer would rather own
even though the stock hasn't "acted as well" as rivals such as
At the time of publication, Cramer was long Caterpillar.
Jim Cramer is a director and co-founder of TheStreet.com. He contributes daily market commentary for TheStreet.com's sites and serves as an adviser to the company's CEO. Outside contributing columnists for TheStreet.com and RealMoney.com, including Cramer, may, from time to time, write about stocks in which they have a position. In such cases, appropriate disclosure is made. To see his personal portfolio and find out what trades Cramer will make before he makes them, sign up for
Action Alerts PLUS. Watch Cramer on "Mad Money" weeknights on CNBC. Click
here to order Cramer's latest book, "Mad Money: Watch TV, Get Rich," click
here to order his book, "Real Money: Sane Investing in an Insane World," click
here to get his second book, "You Got Screwed!" and click
here to order Cramer's autobiography, "Confessions of a Street Addict." While he cannot provide personalized investment advice or recommendations, he invites you to send comments on his column by
TheStreet.com has a revenue-sharing relationship with Traders' Library under which it receives a portion of the revenue from Traders' Library purchases by customers directed there from TheStreet.com.